Nutriband Inc.

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%
HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

At a Glance

Live Snapshot
Market Cap$50.45M
EPS-0.9900
P/E Ratio-4.19
Earnings Date04/27/2026

ntrb

Additional Paid-In Capital

Last Annual Value

45.03M

3-Year CAGR

15%

5-Year CAGR

38%

10-Year CAGR

135%

Nutriband Inc.

Nutriband Inc. Competitors Analysis of Additional Paid-In Capital

NTRB · NASDAQ
CompanyAdditional Paid-In Capital
CAGR 3Y
CAGR 5Y
CAGR 10Y
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
45.03M
9.3%8.5%73.4% 
627.98M
16.4%19.9%N/A
784.71M
6.7%8.9%24.6%
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
0.00
N/AN/AN/A
387.25M
17.7%225.9%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
773.79M
12.0%10.4%N/A
119.14M
17.7%16.4%N/A
12.83M
5.9%12.3%187.6%
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
548.13M
5.4%6.1%13.1%
IMA logo
ImageneBio Inc
NASDAQ:IMA
363.09M
-7.1%0.5%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
599.24M
11.2%13.1%7.1%
Nutriband Inc.

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

Intrinsic Value
Current Price: $4.15